2013 Perspectives In Rheumatic Diseases Conference Highlights CME Post Test

8 Questions | Total Attempts: 179

SettingsSettingsSettings
Please wait...
2013 Perspectives In Rheumatic Diseases Conference Highlights CME Post Test


Questions and Answers
  • 1. 
    1. More than ___% of patients with rheumatoid arthritis have radiographic abnormalities within 2 years of diagnosis.
    • A. 

      60%

    • B. 

      70%

    • C. 

      80%

    • D. 

      90%

  • 2. 
    According to the ACR/EULAR classification criteria published in 2010, a diagnosis of “definite RA” is indicated by a score of ___ or more out of a possible 10.
    • A. 

      2

    • B. 

      4

    • C. 

      6

    • D. 

      8

  • 3. 
    The concept of treating to target began to emerge as an accepted clinical strategy following publication of:
    • A. 

      A. The ACR EULAR classification criteria

    • B. 

      B. The ADACTA (ADalamumab ACTemrA) study

    • C. 

      C. The Clinical Disease Activity Index (CDAI)

    • D. 

      D. The Tight Control for Rheumatoid Arthritis (TICORA) trial

  • 4. 
    Which one of the following assessment tools relies entirely on patient-reported data?
    • A. 

      A. Clinical Disease Activity Index (CDAI)

    • B. 

      B. Disease Activity Score

    • C. 

      C. Routine Assessment of Patient Index Data (RAPID)-3

    • D. 

      D. Simplified Disease Activity Index (SDAI)

  • 5. 
    _____ is the first trial to compare two biologic agents in patients with rheumatoid arthritis who had not responded adequately to methotrexate.
    • A. 

      A. The ADACTA study

    • B. 

      B. The AMPLE study

    • C. 

      C. The MDA study

    • D. 

      D. The TICORA trial

  • 6. 
    The GRAPPA approach has demonstrated that ________ is the class of drugs that has been shown to affect the status of all five domains of psoriatic arthritis.
    • A. 

      A. Anti-tumor necrosis factor agents

    • B. 

      B. Biologics

    • C. 

      C. Interleukins

    • D. 

      D. JAK inhibitors

  • 7. 
    In patients with psoriasis, numerous studies have demonstrated that tumor necrosis factor inhibitors have demonstrated therapeutic synergy with ________.
    • A. 

      A. Interleukin-12/23 inhibitors

    • B. 

      B. Methotrexate

    • C. 

      C. Systemic corticosteroids

    • D. 

      D. Vitamin D analogs

  • 8. 
    The use of TNF inhibitors in ______ is complicated by a lack of supporting data in controlled clinical trials.
    • A. 

      A. Elderly patients

    • B. 

      B. Patients with comorbid conditions

    • C. 

      C. Pediatric patients

    • D. 

      D. Psoriasis

Back to Top Back to top